The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

U	NITED STATES SECURITIE	S AND EXCHANG	E COMMISSION	OMB APPROV	/AL
		ton, D.C. 20549		OMB Number:	3235-0076
	F	ORM D		Estimated average burden	
	Notice of Exempt	Offering of Secur	itios	hours per response:	4.00
		Contening of Secur	ities		
1. Issuer's Identity					
	Previous	Π			
CIK (Filer ID Number)	Names	None	Entity Type		
0001372514		ARMACEUTICALS	X Corporation		
Name of Issuer	INC		Limited Partnershi	р	
KIORA PHARMACEUTICALS INC			Limited Liability Co	ompany	
Jurisdiction of Incorporation/Organ	nization		General Partnersh		
DELAWARE Year of Incorporation/Organization				пÞ	
	I		Business Trust		
X Over Five Years Ago			Other (Specify)		
Within Last Five Years (Specify	/ Year)				
Yet to Be Formed					
2. Principal Place of Business ar	nd Contact Information				
Name of Issuer					
KIORA PHARMACEUTICALS INC					
Street Address 1		Street Address 2			
332 ENCINITAS BOULEVARD		SUITE 102			
City	State/Province/Country	ZIP/PostalCode	Phone Number of Is	suer	
ENCINITAS	CALIFORNIA	92024	781-788-9043		
3. Related Persons					
Last Name	First Name		Middle Name		
Strem	Brian				
Street Address 1	Street Address 2				
332 Encinitas Blvd, Suite 102					
City	State/Province/Coun	try	ZIP/PostalCode		
Encinitas	CALIFORNIA		92024		
Relationship: X Executive Officer	X Director Promoter				
Clarification of Response (if Neces	sary):				
President and Chief Executive Officer					
Last Name	First Name		Middle Name		
Tosca	Melissa				
Street Address 1	Street Address 2				
332 Encinitas Blvd, Suite 102					
City	State/Province/Coun	try	ZIP/PostalCode		
Encinitas	CALIFORNIA		92024		
Relationship: X Executive Officer	Director				
Clarification of Response (if Neces	sary):				
Executive VP of Finance					
Last Name	First Name		Middle Name		
Daniels	Eric				
Street Address 1	Street Address 2				
332 Encinitas Blvd, Suite 102					
City	State/Province/Coun	try	ZIP/PostalCode		
Encinitas	CALIFORNIA		92024		

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Chief Development Officer		
Last Name	First Name	Middle Name
Chaney	Paul	
Street Address 1	Street Address 2	
	Offeet Address 2	
332 Encinitas Blvd, Suite 102	Otata (Dara in a c /O a untra	
City	State/Province/Country	ZIP/PostalCode
Encinitas	CALIFORNIA	92024
Relationship: Executive Officer X Director	Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Shapiro	Aron	
Street Address 1	Street Address 2	
332 Encinitas Blvd, Suite 102		
City	State/Province/Country	ZIP/PostalCode
Encinitas	CALIFORNIA	92024
Relationship: Executive Officer X Director	Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Gayron	Kenneth	
Street Address 1	Street Address 2	
332 Encinitas Blvd, Suite 102		
City	State/Province/Country	ZIP/PostalCode
Encinitas	CALIFORNIA	92024
		,
Relationship: Executive Officer X Director	Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Tyle	Praveen	
Street Address 1	Street Address 2	
332 Encinitas Blvd, Suite 102		
	State/Brayinga/Country	ZIP/PostalCode
City	State/Province/Country	
Encinitas	CALIFORNIA	92024
Relationship: Executive Officer X Director	Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Hollander	David	
Street Address 1	Street Address 2	
332 Encinitas Blvd, Suite 102		
City	State/Province/Country	ZIP/PostalCode
Encinitas	CALIFORNIA	92024
		2024
Relationship: Executive Officer X Director	Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Parsons	Erin	
Street Address 1	Street Address 2	
332 Encinitas Blvd, Suite 102		
City	State/Province/Country	ZIP/PostalCode
Encinitas	CALIFORNIA	92024
Relationship: Executive Officer Director	Promoter	

Clarification of Response (if Necessary):

4. Industry Group

Agriculture	Health Care	Retailing
Banking & Financial Services	Biotechnology	Restaurants
Commercial Banking	Health Insurance	
Insurance		Technology
Investing	Hospitals & Physicians	Computers
Investment Banking	X Pharmaceuticals	Telecommunications
Pooled Investment Fund	Other Health Care	Other Technology
Is the issuer registered as	Manufacturing	Travel
an investment company under the Investment Company	Real Estate	Airlines & Airports
Act of 1940?	Commercial	Lodging & Conventions
Yes	Construction	
Other Banking & Financial Services		Tourism & Travel Services
Business Services	REITS & Finance	Other Travel
Energy	Residential	Other
	Other Real Estate	
Coal Mining		
Electric Utilities		

5. Issuer Size

Oil & Gas

Energy Conservation

Revenue Range	OR A	Aggregate Net Asset Value Range
No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000		Over \$100,000,000
X Decline to Disclose		Decline to Disclose
Not Applicable	Ī	Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

	Investment Company Act Section 3(c)	
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1)	Section 3(c)(9)
Rule 504 (b)(1)(i)	Section 3(c)(2)	Section 3(c)(10)
Rule 504 (b)(1)(ii)	Section 3(c)(3)	Section 3(c)(11)
Rule 504 (b)(1)(iii)	Section 3(c)(4)	Section 3(c)(12)
X Rule 506(b) Rule 506(c)	Section 3(c)(5)	Section 3(c)(13)
Securities Act Section 4(a)(5)	Section 3(c)(6)	Section 3(c)(14)
	Section 3(c)(7)	

7. Type of Filing

X New Notice Date of First Sale 2023-02-03 First Sale Yet to Occur

Amendment

8. Duration of Offering		
Does the Issuer intend this offering to last more than one year?	es X No	
9. Type(s) of Securities Offered (select all that apply)		
X Equity Debt X Option, Warrant or Other Right to Acquire Another Security Security to be Acquired Upon Exercise of Option, Warrant or Other F Acquire Security	Pooled Investment Fund Interests Tenant-in-Common Securities Mineral Property Securities Right to Other (describe)	
10. Business Combination Transaction		
Is this offering being made in connection with a business combination to or exchange offer?	transaction, such as a merger, acquisition	
Clarification of Response (if Necessary):		
11. Minimum Investment		
Minimum investment accepted from any outside investor \$0 USD		
12. Sales Compensation		
Recipient	Recipient CRD Number X None	
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number X None	
Street Address 1	Street Address 2	
	State/Province/Country	ZIP/Postal Code
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	Foreign/non-US	
13. Offering and Sales Amounts		
Total Offering Amount \$200,000 USD or Indefinite Total Amount Sold \$200,000 USD Total Remaining to be Sold \$0 USD or Indefinite Clarification of Response (if Necessary): Total Offering Amount represents up to \$10,000,000 of common stock that mathe issuer's Current Report on Form 8-K filed on February 3, 2023.	ay be issued in the future pursuant to a Purchase Agreement between the is	suer and the investor. See
14. Investors		
Select if securities in the offering have been or may be sold to personal such non-accredited investors who already have invested in the offer Regardless of whether securities in the offering have been or may be total number of investors who already have invested in the offering:	ering. be sold to persons who do not qualify as accredited investors, enter	
15. Sales Commissions & Finder's Fees Expenses		
Provide separately the amounts of sales commissions and finders fees check the box next to the amount.	expenses, if any. If the amount of an expenditure is not known, prov	vide an estimate and
Sales Commissions \$0 USD Estimate		
Finders' Fees \$0 USD Estimate		
Clarification of Response (if Necessary):		
16. Use of Proceeds		
Provide the amount of the gross proceeds of the offering that has been executive officers, directors or promoters in response to Item 3 above. I		
\$0 USD Estimate		
Clarification of Response (if Necessary):		

Some of the proceeds may be used for working capital and other general corporate purposes, which may include the payment of salaries and other fees to those listed in Item 3.

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration brought against the issuer is that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
KIORA PHARMACEUTICALS INC	/s/ Melissa Tosca	Melissa Tosca	EVP of Finance	2023-02-17

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.